Exact Sciences has awarded $1.3 million to 23 organizations through its Funding Opportunities for Colorectal Screening Uptake Strategies (FOCUS) Program, the company announced today. According to a release, the FOCUS…
Exact Sciences announced today that it acquired Resolution Bioscience from Agilent Technologies. According to a release, Resolution Bioscience’s blood-based diagnostic tests complement Exact Sciences’ Precision Oncology portfolio, providing a more…
Exact Sciences is partnering with two renowned healthcare organizations at the forefront of cancer research, the Broad Institute of MIT and Harvard along with Baylor Scott & White, the company…
Exact Sciences plans to submit next-generation Cologuard tests for FDA approval, the company announced recently. According to a release, the results from its BLUE-C study saw 94 percent sensitivity for…
Exact Sciences’ announced today its initial clinical validation data for its Profile for the Omission of Local Adjuvant Radiotherapy (POLAR). According to a release, POLAR is the first genomic signature…
Exact Sciences announced recently that it acquired PreventionGenetics, a clinical DNA testing laboratory located in Marshfield, Wis. According to a release, PreventionGenetics will provide the clinical lab, expertise and technology…
Exact Sciences and Jefferson Health are collaborating to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test, the company announced recently. According to a release, the joint effort…
Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently. According…
Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. According to…
Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today. According to a release, the Oncotype MAP…
